Cary Street Partners Asset Management’s AstraZeneca AZN Stock Holding History

Cary Street Partners Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-300	Closed	-$41.6K	–	207
2023 Q1	$41.6K	Hold	300	–	–	0.01%	249
2022 Q4	$40.7K	Hold	300	–	–	0.01%	276
2022 Q3	$33K	Buy	+300	New	+$38.1K	0.01%	243

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cary Street Partners Asset Management's AZN Position: Q2 2023 in Review

Cary Street Partners Asset Management sold out of AstraZeneca (AZN) in Q2 2023, closing a stake of 300 shares — an estimated $41.6K sold.

Cary Street Partners Asset Management first reported a position in AZN in Q3 2022 and held it in 3 quarters. The position peaked at $41.6K in Q1 2023. 1,092 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

Cary Street Partners Asset Management reported no remaining AstraZeneca position as of Q2 2023 after selling out during the quarter.
Cary Street Partners Asset Management sold 300 AstraZeneca shares in Q2 2023, an estimated $41.6K.
Cary Street Partners Asset Management first reported a position in AstraZeneca in Q3 2022 and held it in 3 quarters.
Cary Street Partners Asset Management's AstraZeneca position peaked at $41.6K in Q1 2023.
1,092 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on Cary Street Partners Asset Management's 13F filing for Q2 2023, filed 10 Aug 2023.